The American Society of Hematology (ASH) shared a post on X about a recent article by Sudipto Mukherjee at al. published in Blood Neoplasia:
“Hypomethylating agents are the best treatment for high-risk MDS, yet they’re underused.
A study shows many eligible patients don’t receive them or stop early, especially female and non-white patients.”
Title: Disparities in Real-World Treatment Patterns of Hypomethylating Agents Among Patients with Myelodysplastic Syndromes in the US
Authors: Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani, Moaath K. Mustafa Ali, John Molina J, Sophia Balderman, Akriti Jain, Paolo Caimi, Faiz Anwer, Mikkael A. Sekeres, Siran M. Koroukian
Read the Full Artcle on Blood Neoplasia
More posts featuring American Society of Hematology.
